The Latin America, Middle East and Africa Clot Busting Drugs Market should witness market growth of 12.0% CAGR during the forecast period (2023-2030).
Inactivity, blood vessel injury, illnesses, genetic disorders, pregnancy, obesity, and smoking primarily bring thrombosis. As cardiovascular disorders become more prevalent, the market is growing significantly. Ischemic strokes and other cardiovascular conditions constitute a severe hazard to public health globally. Several problems occur when a blood clot restricts blood flow to the heart or brain. Clot-busting drugs, such as tissue plasminogen activator (tPA), are crucial for restoring blood flow and minimizing the damage caused by these diseases.
Cardiovascular illnesses are becoming increasingly prevalent because of sedentary lifestyles, bad diets, tobacco use, and an ageing population. As a result of this expanding prevalence, there is a rising demand for effective therapy, such as clot-busting drugs. Additionally, the development and modernization of emergency medical services (EMS) systems are to blame for the rise in cardiovascular emergency detection and response times.
The 2012 World Bank report estimates that 4.7% of the 336 million inhabitants of the Middle East and Northern Africa (MENA) are aged 65 or older. The nation of South Africa has an estimated population of 56.5 million people, according to Statistics South Africa’s most recent mid-year population predictions. The healthcare industry has grown over the past 10 years to become one of the GCC’s most important sectors for promoting economic diversification. All of these variables are anticipated to have a beneficial effect on the growth of the regional market.
The Brazil market dominated the LAMEA Clot Busting Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $993.9 million by 2030. The Argentina market is estimated to grow at a CAGR of 12.6% during (2023-2030). Additionally, The UAE market would exhibit a CAGR of 11.7% during (2023-2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product, the market is segmented into Anticoagulants, Thrombolytic Drugs, Anti-Platelet Drugs and Others. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Indication, the market is segmented into Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Eli Lilly And Company, Johnson & Johnson (Johnson & Johnson Services, Inc.), Pfizer, Inc., Merck & Co., Inc.
Inactivity, blood vessel injury, illnesses, genetic disorders, pregnancy, obesity, and smoking primarily bring thrombosis. As cardiovascular disorders become more prevalent, the market is growing significantly. Ischemic strokes and other cardiovascular conditions constitute a severe hazard to public health globally. Several problems occur when a blood clot restricts blood flow to the heart or brain. Clot-busting drugs, such as tissue plasminogen activator (tPA), are crucial for restoring blood flow and minimizing the damage caused by these diseases.
Cardiovascular illnesses are becoming increasingly prevalent because of sedentary lifestyles, bad diets, tobacco use, and an ageing population. As a result of this expanding prevalence, there is a rising demand for effective therapy, such as clot-busting drugs. Additionally, the development and modernization of emergency medical services (EMS) systems are to blame for the rise in cardiovascular emergency detection and response times.
The 2012 World Bank report estimates that 4.7% of the 336 million inhabitants of the Middle East and Northern Africa (MENA) are aged 65 or older. The nation of South Africa has an estimated population of 56.5 million people, according to Statistics South Africa’s most recent mid-year population predictions. The healthcare industry has grown over the past 10 years to become one of the GCC’s most important sectors for promoting economic diversification. All of these variables are anticipated to have a beneficial effect on the growth of the regional market.
The Brazil market dominated the LAMEA Clot Busting Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $993.9 million by 2030. The Argentina market is estimated to grow at a CAGR of 12.6% during (2023-2030). Additionally, The UAE market would exhibit a CAGR of 11.7% during (2023-2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product, the market is segmented into Anticoagulants, Thrombolytic Drugs, Anti-Platelet Drugs and Others. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Indication, the market is segmented into Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Eli Lilly And Company, Johnson & Johnson (Johnson & Johnson Services, Inc.), Pfizer, Inc., Merck & Co., Inc.
Scope of the Study
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Product
- Anticoagulants
- Thrombolytic Drugs
- Anti-Platelet Drugs
- Others
By Route of Administration
- Injectable
- Oral
By Indication
- Pulmonary Embolism
- Atrial Fibrillation
- Deep Vein Thrombosis
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Sanofi S.A.
- Dr. Reddy’s Laboratories Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Eli Lilly And Company
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Pfizer, Inc.
- Merck & Co., Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Clot Busting Drugs Market by Distribution Channel
Chapter 5. LAMEA Clot Busting Drugs Market by Product
Chapter 6. LAMEA Clot Busting Drugs Market by Route of Administration
Chapter 7. LAMEA Clot Busting Drugs Market by Indication
Chapter 8. LAMEA Clot Busting Drugs Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Sanofi S.A.
- Dr. Reddy’s Laboratories Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Eli Lilly And Company
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Pfizer, Inc.
- Merck & Co., Inc.
Methodology
LOADING...
